Eye drops containing a derivative of turmeric reduce the loss of retinal cells in rats, finds a new study led by UCL and Imperial College London researchers.
Loss of these cells is known to be an early sign of glaucoma and the eye drops could in time be a new treatment option for the condition.
In the new Scientific Reports paper, the researchers report a new method to deliver curcumin, extracted from the yellow spice turmeric, directly to the back of the eye using eye drops, overcoming the challenge of curcumin’s poor solubility.
They are also investigating how the eye drops could be used as a diagnostic tool for a range of conditions.
“Curcumin is an exciting compound that has shown promise at detecting and treating the neurodegeneration implicated in numerous eye and brain conditions from glaucoma to Alzheimer’s disease, so being able to administer it easily in eye drops may end up helping millions of people,” said the study’s lead author, Professor Francesca Cordeiro (UCL Institute of Ophthalmology, Western Eye Hospital and Imperial College London).
Glaucoma is a group of eye conditions affecting over 60 million people worldwide that leads to irreversible blindness in 1 in 10 cases. The condition mainly involves the loss of retinal ganglion cells, a type of neuron located near the surface of the retina. Stopping the loss of these cells early on has not yet been achieved, so it is a key focus of glaucoma research.
Curcumin has previously been shown to protect retinal ganglion cells when administered orally. For the current study, the researchers were seeking to find a more reliable method to deliver curcumin. Oral administration is difficult because curcumin has poor solubility, so it does not easily dissolve and get absorbed into the bloodstream, and would require people to take large amounts of tablets (up to 24 a day) that may cause gastrointestinal side effects.
The team developed a novel nanocarrier, wherein the curcumin is contained within a surfactant combined with a stabiliser, both of which are known to be safe for human use and are already in existing eye products. The nanocarrier can be used in eye drops to deliver much higher loads of curcumin than other products in development, increasing the drug’s solubility by a factor of almost 400,000, and localises the curcumin in the eyes instead of throughout the body.
The researchers initially tested the product on cells that are used to model glaucoma, before conducting trials in rats with eye conditions involving the loss of retinal ganglion cells.
After twice-daily use of eye drops in the rats for three weeks, retinal ganglion cell loss was significantly reduced compared to matched controls, and the treatment was found to be well-tolerated with no signs of eye irritation or inflammation.
Having found an effective way to deliver curcumin, the researchers are hopeful that it could also be used to diagnose Alzheimer’s disease, as curcumin is known to bind to the amyloid beta protein deposits implicated in Alzheimer’s, and can be detected in the retina with fluorescence to highlight the malignant proteins.
“We are now researching diagnostic uses for these eye drops alongside other ways to visualise the retina, as eye tests can be an opportunity to detect signs of neurodegeneration with a simple, non-invasive test,” said co-lead author Dr Ben Davis (UCL Institute of Ophthalmology and Imperial College London).
Professor Cordeiro added: “As we live longer, diseases such as glaucoma and Alzheimer’s are steadily increasing. We believe our findings could make a major contribution at helping the lives of people affected by these devastating diseases.”
The Latest on: Glaucoma
via Google News
The Latest on: Glaucoma
- Surgical Lasers Market Demand Expected to Raise by Rising Prevalence of Glaucoma and Cataract in Near Future on April 18, 2019 at 8:01 am
Apr 18, 2019 (AmericanNewsHour via COMTEX) -- The global surgical lasers market is segmented into product type such as carbon dioxide, Argon, ND:Yag, diode lasers and other surgical lasers. Among ... […]
- Minimally Invasive Glaucoma Surgery (MIGS) Devices Market to Witness a CAGR of 39.1% during 2018-2024 on April 18, 2019 at 6:35 am
NEW YORK, April 18, 2019 (GLOBE NEWSWIRE) -- The global minimally invasive glaucoma surgery (MIGS) devices market is expected to witness a CAGR of 39.1%, and is projected to reach USD 2392.5 million ... […]
- New Study: Glaucoma Surgical Equipment Market to Perceive Substantial Growth During 2018-2025 on April 17, 2019 at 6:31 pm
Glaucoma is a set of eye diseases that affects optic nerve of eye, thus resulting in vision loss and bilateral, irreversible blindness. It is the second most common cause of blindness worldwide. ... […]
- Glaukos touts 5-year study of glaucoma stents on April 15, 2019 at 12:52 pm
Glaukos (NYSE: GKOS) said today that a study of its iStent trabecular micro-bypass stents reduced eye pressure in glaucoma patients five years after implant. The same study showed that significantly ... […]
- How Lagos woman Discovered eye treatment Remedy that Reverses Glaucoma, Cataracts and Improves Eyesight without eyedrops or surgery on April 14, 2019 at 8:00 am
Glaucoma. Cataracts. Blurry vision. Age-related Macular Degeneration (AMD). Myopia. If not detected and treated early, these are vision problems in the elderly that could lead to partial or complete ... […]
- Risk of aphakic glaucoma after pars plana-lensectomy with and without removal of the peripheral lens capsule on April 12, 2019 at 3:59 pm
The etiology of aphakic glaucoma is unclear. It has been suggested that remaining lens epithelium releases cytokines transducing trabecular meshwork cells. Therefore, we compared two cohorts of ... […]
- Get the facts on Glaucoma on April 11, 2019 at 3:14 pm
GRAND RAPIDS, Mich. (WOTV) - For years, Andrew Iwach, executive director of the Glaucoma Center of San Francisco, has been trying to convince patients to kick their smoking habit. Words like emphysema ... […]
- Correlation between structural progression in glaucoma and obstructive sleep apnea on April 10, 2019 at 1:18 am
To investigate the correlation between obstructive sleep apnea (OSA) severity and the structural and functional progression in patients with glaucoma. This retrospective comparative cohort study ... […]
- Glaucoma Pharmaceuticals Market is Expected to Exhibit US$ 6.0 Billion by 2024 on April 9, 2019 at 11:53 am
Apr 09, 2019 (Heraldkeeper via COMTEX) -- New York, April 09, 2019: The Glaucoma Pharmaceuticals Market is expected to exceed more than US$ 6.0 Billion by 2024 at a CAGR of 5.1% in the given forecast ... […]
via Bing News